Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Zacks Investment Research7/9/2026Positive
REGN
Regeneron Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$70.90B
P/E Ratio
15.87
EPS
$42.60
Beta
0.24
52W High
$818.90
52W Low
$538.55
50-Day MA
$653.81
200-Day MA
$700.73
Dividend Yield
0.55%
Profit Margin
29.60%
Forward P/E
14.47
PEG Ratio
1.12
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Fundamentals
| Revenue (TTM) | $14.92B |
| Gross Profit (TTM) | $6.55B |
| EBITDA | $4.38B |
| Operating Margin | 20.70% |
| Return on Equity | 14.50% |
| Return on Assets | 6.13% |
| Revenue/Share (TTM) | $143.56 |
| Book Value | $308.32 |
| Price-to-Book | 2.17 |
| Price-to-Sales (TTM) | 4.75 |
| EV/Revenue | 4.161 |
| EV/EBITDA | 10.81 |
| Quarterly Earnings Growth (YoY) | -7.20% |
| Quarterly Revenue Growth (YoY) | 19.00% |
| Shares Outstanding | $103.02M |
| Float | $97.67M |
| % Insiders | 2.03% |
| % Institutions | 92.22% |
Historical Volatility
HV 10-Day
35.01%
HV 20-Day
27.47%
HV 30-Day
28.66%
HV 60-Day
35.75%
HV Rank
36.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($822.48 target)
5
Strong Buy16
Buy8
HoldLatest News
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks Investment Research7/7/2026Positive
Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
24/7 Wall Street7/7/2026Positive
Here's Why Regeneron (REGN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research7/7/2026Positive
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Zacks Investment Research7/7/2026Positive
Why Regeneron (REGN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research7/2/2026Positive
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron , among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC reported on Monday citing an FDA spokesperson.
Reuters6/29/2026Positive
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck program is designed to accelerate regulatory review of new pharmaceutical manufacturing facilities.
CNBC6/29/2026Positive
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
GlobeNewsWire6/25/2026Neutral
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.
Zacks Investment Research6/23/2026Positive
More HEALTHCARE Stocks
Data last updated: 7/9/2026